Zentek (CVE:ZEN) Upgraded to “Strong-Buy” at Atrium Research

Atrium Research upgraded shares of Zentek (CVE:ZEN) to a strong-buy rating in a research note issued to investors on Monday morning,Zacks reports.

Zentek Trading Up 5.6%

Zentek stock opened at C$0.76 on Monday. The company has a debt-to-equity ratio of 7.62, a current ratio of 4.65 and a quick ratio of 7.59. The stock has a market capitalization of C$96.23 million, a PE ratio of -7.84 and a beta of 0.33. The business’s fifty day moving average is C$0.78 and its 200 day moving average is C$0.77. Zentek has a one year low of C$0.52 and a one year high of C$1.50.

About Zentek

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It is also developing graphene oxide synthesis and graphene synthesis. In addition, the company owns 100% interest in the Albany graphite project located in Northern Ontario, Canada.